Amgen – Inclisiran now has its cost-effectiveness report from ICER. Should Novartis be concerned?
Amgen - Inclisiran now has its cost-effectiveness report from ICER. Should Novartis be concerned? The PCSK9 cholesterol drug class was ...
Home » ICER
Amgen - Inclisiran now has its cost-effectiveness report from ICER. Should Novartis be concerned? The PCSK9 cholesterol drug class was ...